Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 262

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

Open access
Kim, Richard D., Sarker, Debashis, Meyer, Tim, Yau, Thomas, Macarulla, Teresa, Park, Joong-Won, Choo, Su Pin, Hollebecque, Antoine, Sung, Max W., Lim, Ho-Yeong, Mazzaferro, Vincenzo, Trojan, Joerg, Zhu, Andrew X., Yoon, Jung-Hwan, Sharma, Sunil, Lin, Zhong-Zhe, Chan, Stephen L., Faivre, Sandrine, Feun, Lynn G., Yen, Chia-Jui, Dufour, Jean-Francois, Palmer, Daniel H., Llovet, Josep M., Manoogian, Melissa, Tugnait, Meera, Stransky, Nicolas, Hagel, Margit, Kohl, Nancy E., Lengauer, Christoph, Sherwin, Cori Ann, Schmidt-Kittler, Oleg, Hoeflich, Klaus P., Shi, Hongliang, Wolf, Beni B., Kang, Yoon-Koo · 2019 · Cancer Discovery

Abstract

Outcomes for patients with advanced hepatocellular carcinoma (HCC) remain poor despite recent progress in drug development. Emerging data implicate FGF19 as a potential HCC driver, suggesting its receptor, FGFR4, as a novel therapeutic target. We evaluated fisogatinib (BLU-554), a highly potent and selective oral FGFR4 inhibitor, in a phase I dose-escalation/dose-expansion study in advanced HCC using FGF19 expression measured by IHC as a biomarker for pathway activation. For dose escalation, 25 patients received 140 to 900 mg fisogatinib once daily; the maximum tolerated dose (600 mg once daily) was expanded in 81 patients. Fisogatinib was well tolerated; most adverse events were manageable, grade 1/2 gastrointestinal events, primarily diarrhea, nausea, and vomiting. Across doses, the overall response rate was 17% in FGF19-positive patients [median duration of response: 5.3 months (95% CI, 3.7–not reached)] and 0% in FGF19-negative patients. These results validate FGFR4 as a targetable driver in FGF19-positive advanced HCC. Significance: Fisogatinib elicited clinical responses in patients with tumor FGF19 overexpression in advanced HCC. These results validate the oncogenic driver role of the FGFR4 pathway in HCC and the use of FGF19 as a biomarker for patient selection. See related commentary by Subbiah and Pal, p. 1646. This article is highlighted in the In This Issue feature, p. 1631

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-19-0555

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 262

Metadata

Authors
Kim, R. D., Sarker, D., Meyer, T., Yau, T., Macarulla, T., Park, J.-W., Choo, S. P., Hollebecque, A., Sung, M. W., Lim, H.-Y., Mazzaferro, V., Trojan, J., Zhu, A. X., Yoon, J.-H., Sharma, S., Lin, Z.-Z., Chan, S. L., Faivre, S., Feun, L. G., Yen, C.-J., Dufour, J.-F., Palmer, D. H., Llovet, J. M., Manoogian, M., Tugnait, M., Stransky, N., Hagel, M., Kohl, N. E., Lengauer, C., Sherwin, C. A., Schmidt-Kittler, O., Hoeflich, K. P., Shi, H., Wolf, B. B., & Kang, Y.-K.
Venue
Cancer Discovery
Published
2019-12-01
Volume
9
Issue
12
Pages
1696-1707
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2977600124
Cited by
262
References
31
FWCI
8.38
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1158/2159-8290.cd-19-0555
The paper
Kim, R. D., Sarker, D., Meyer, T., Yau, T., Macarulla, T., Park, J.-W., Choo, S. P., Hollebecque, A., Sung, M. W., Lim, H.-Y., Mazzaferro, V., Trojan, J., Zhu, A. X., Yoon, J.-H., Sharma, S., Lin, Z.-Z., Chan, S. L., Faivre, S., Feun, L. G., . . . Kang, Y.-K. (2019). First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-19-0555

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.